Sinotherapeutics, Inc. Class ASSE: 688247

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets

· Issued by Sinotherapeutics, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis